

Curriculum Vitae

Personal Data

Title	Prof. Dr.
First name	Elvir
Name	Becirovic
Current institution(s)/site(s), country	University of Zurich (UZH) and University Hospital Zurich (USZ)
Identifiers/ORCID	Web of Science: ABE-6710-2020 ORCID: https://orcid.org/0000-0001-8801-0649

Qualifications and Career

Stages	Periods and Details
Degree programme	Study of Biology, 2001-2006 , University of Cologne, Germany. Degree: Diploma
Doctorate	Date: May 20, 2010 , Supervisor: Prof. Dr. Martin Biel, Faculty of Chemistry and Pharmacy/ Department Pharmacy - Center for Drug Research, LMU Munich/ Germany
Stages of academic/professional career (<i>optional after doctorate</i>)	<p>2022 – Assistant Professor for Experimental and Translational Ophthalmology, University of Zurich</p> <p>2019: ‘Venia legendi’ and ‘Facultas docendi’ in Pharmacology Faculty of Chemistry and Pharmacy/ Department Pharmacy - Center for Drug Research, LMU Munich/ Germany</p> <p>2019 – Chief Technology Advisor for ViGeneron GmbH, a Gene Therapy Company</p> <p>2010-2014: Postdoctoral Fellow, Faculty of Chemistry and Pharmacy/ Department Pharmacy - Center for Drug Research, LMU Munich/ Germany</p> <p>2014-2022: Group Leader “Innovative Gene Therapy Approaches”, Faculty of Chemistry and Pharmacy/ Department Pharmacy - Center for Drug Research, LMU Munich/ Germany</p>

Supplementary Career Information

PARENTAL LEAVE: Jan-March 2015 (three months) and July-Sept 2016 (three months).

Activities in the Research System

REVIEWING ACTIVITIES

- 2016 – Review Board Frontiers in Neuroscience,
 2016 – Ad hoc reviewer for Nature Communications, FASEB J, Cell Communication and Signaling, Scientific Reports, Cellular and Molecular Life Sciences, PloS ONE

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

- 2022 – Graduate School for Neurosciences and Graduate School for Biomedicine (Life Science Graduate School Zurich, LSGSZ)
 2020 – Research Network “German Society for Gene Therapy”
 2019 – Research Network “European Society for Gene and Cell Therapy (ESGCT)”
 2016 – Research Network “The Association for Research in Vision and Ophthalmology (ARVO)”

RESEARCH GRANTS (Selection)

- 2023 – 2027 Title: *Cross-generational epigenetic effects of gene therapies*, Funded by: The Swiss National Science Foundation (SNSF), individual grant
 2022 – 2024 Title: *Novel dual rAAV vectors for (epi)genome editing-based therapy of gain-of-function mutations*, Funded by: SNSF, individual grant
 2021 – 2024 Title: *Establishment of a novel approach for molecular diagnosis of inherited retinal dystrophies*, Funded by: Helmut-Ecker-Stiftung
 2018 – 2021 Title: *A novel treatment approach for achromatopsia and retinitis pigmentosa using VPR-Cas9 mediated gene activation*, Funded by: The German Research Foundation (DFG), Priority Program
 2014 – 2017 Title: *In vivo analysis of disease-associated mutations in peripherin-2: characterization of pathomechanisms and development of a miRNA-based gene therapy for autosomal dominant retinitis pigmentosa*; Funded by: DFG, individual grant

PATENTS

- Becirovic E**, Michalakis S, Biel M. *An optimized acceptor splice site module for biological and biotechnological applications*. (2018) WO2020127831A1
Becirovic E, Michalakis S, Biel M, Riedmayr L, Splith V, Böhm S. *Method of transactivating a homologous gene of a gene of interest and an in vitro method of diagnosing a disease*. (2020) WO2021058543

Academic Distinctions

- 2023 RD2023 Travel Award for Junior Faculty
 2021 Grant of the Volkswagenstiftung, Research Initiative ‘Experiment!’
 2019, 2020 Highly Cited Researcher Recipient in Pharmacology and Toxicology, Web of Science Group
 2018 USH2018 Poster Award
 2017 ARVO (The Association for Research in Vision and Ophthalmology) Outstanding Poster Award
 2017 ARVO Travel Grant
 2016 Retinitis Pigmentosa Research Award of the PRO RETINA Deutschland e. V. and the Retina Suisse Foundation